Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease

Arthritis and Rheumatism

Volumn 56, Issue 12, 2007, Pages 4195-4202

  Mittoo, Shikha ^a   Wigley, Fredrick M ^a   Wise, Robert ^a   Xiao, Huiqing ^a   Hummers, Laura ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCLERODERMA; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; BRONCHOALVEOLAR LAVAGE; CYCLOPHOSPHAMIDE; EOSINOPHILS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 37149037975     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23077     Document Type: Article

References (20)

1. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28:759-67.
2. Owens GR, Fino GJ, Herbert DL, Steen VD, Medsger TA Jr, Pennock BE, et al. Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983;84:546-50.
3. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984;63:221-31.
4. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
5. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88:470-6.
6. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154(2 Pt 1):400-6.
7. Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999;58:635-40.
8. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al, for the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
10. Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspncic patients with systemic sclerosis. Arthritis Rheum 2004;50:1909-17.
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-87.
13. Knudson RJ, Kaltenborn WT, Knudson DE, Burrows B. The single-breath carbon monoxide diffusing capacity: reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987;135:805-11.
14. Becklake MR, Goldman HI. The clinical uses of pulmonary function tests. S Afr Med J 1953;27:16-9.
15. Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, et al. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005;64:1343-6.
16. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.
17. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998;25:1325-9.
18. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
19. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78.
20. Luzina IG, Atamas SP, Wise R, Wigley FM, Choi J, Xiao HQ, et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003;48:2262-74.